Results 51 to 60 of about 15,817 (194)

High Intrahepatic cccDNA in Resolved HBV Infection: Insights From Living Donor Liver Transplantation With Anti‐HBc‐Positive Grafts

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Aim In hepatitis B surface antigen (HBsAg)‐negative recipients with antibody to hepatitis B core antigen (anti‐HBc)‐positive liver grafts, hepatitis B virus (HBV) can be reactivated under post‐transplant immunosuppression. We recently reported a median intrahepatic covalently closed circular DNA (cccDNA) level of 238 copies/μg in HBsAg ...
Sung Kwan Bae, Nobuhisa Akamatsu, Akihiko Ichida, Yujiro Nishioka, Yoshinori Inagaki, Nozomi Miyake, Takeshi Takamoto, Yoshikuni Kawaguchi, Sumihito Tamura, Junichi Arita, Junichi Kaneko, Motoyuki Otsuka, Yasuhito Tanaka, Hiroshi Yotsuyanagi, Kyoji Moriya, Kiyoshi Hasegawa   +15 more
wiley   +1 more source

Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis [PDF]

, 2012
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90203/1/apt4990 ...
Andreone, Belongia, Berg, Boxer, Chu, de Jongh, Fleischer, Fontana, Fontana, Fontana, Gane, Hadziyannis, Hadziyannis, Hann, Jadad, Kamath, Kao, Kim, Lange, Lavanchy, Liaw, Liaw, Liaw, Liaw, Liaw, Liaw, Lok, Manolakopoulos, Nikolaidis, Nishida, Osborn, Pellicelli, Perrillo, Perrillo, Raijnders, Rodriguez -Novoa, Schiff, Schiff, Shim, Tenney, Tseng, van Bommel, Villeneuve, von Elm, Wong, Woo, Yao, Zoulim   +47 more
core   +1 more source

Congenital CMV Infection: Determination of Transplacental Passage of Aciclovir by Ex Vivo Placental Perfusion

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 6, Page 1241-1248, May 2026.
ABSTRACT Objective To quantify the transplacental transfer of aciclovir at an amount equivalent to 2 g of valaciclovir corresponding to the fractionated dosing regimen given four times daily used to reduce congenital cytomegalovirus (CMV) transmission and to treat the CMV‐infected fetus. Design Experimental ex vivo study.
Helyett Ollivier, Valentine Faure Bardon, Leo Froelicher Bournaud, Isidore Gaubert, Tiffany Guilleminot, Marianne Leruez‐Ville, Jean‐Marc Treluyer, Yves Ville, Gabrielle Lui, Julien Stirnemann   +9 more
wiley   +1 more source

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients

Journal of the Formosan Medical Association, 2014
Several anti-viral drugs are approved for the treatment of hepatitis B virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg) can predict the therapeutic response during long-term entecavir treatment remains unclear ...
Chia-Chi Wang, Tai-Chung Tseng, Pin-Chao Wang, Hans Hsienhong Lin, Jia-Horng Kao   +4 more
doaj   +1 more source

Kidney Transplantation From Donors with Hepatitis B [PDF]

, 2016
The growing demand for organ donors to supply the increasing number of patients on kidney waiting lists has led most transplant centers to develop protocols that allow safe use of organs from donors with special clinical situations previously regarded as
Ardita, Vincenzo, Corona, Daniela, Ekser, Burcin, Giaquinta, Alessia, Gozzo, Cecilia, Patanè, Marco, Sinagra, Nunziata, Veroux, Massimiliano, Veroux, Pierfrancesco, Zerbo, Domenico   +9 more
core   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients [PDF]

, 2016
Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients
Fujioka, Shin-ichi, Ikeda, Fusao, Kariyama, Kazuya, Kobashi, Haruhiko, Miyatake, Hirokazu, Morimoto, Yoichi, Morimoto, Yuki, Moriya, Akio, Okamoto, Ryoichi, Seno, Tomonori, Takaguchi, Koichi, Takaki, Akinobu, Takayama, Hiroki, Toshimori, Junichi, Wada, Nozomu, Yabushita, Kazuhisa, Yamamoto, Kazuhide, Yasunaka, Tetsuya   +17 more
core   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang, Jia‐Lan Wang, Su‐Wen Jiang, Ai‐Wu Zhou, Meng‐Han Jin, Hao‐Jin Zhang, Shi‐Qi Yang, Shi‐Yang Fan, Ai‐Rong Hu   +8 more
wiley   +1 more source